GRENKE AG

  • WKN: A161N3
  • ISIN: DE000A161N30
  • Land: Deutschland

Nachricht vom 04.10.2021 | 20:18

GRENKE AG: GRENKE AG: New leasing business in the third quarter adversely affected by supply bottlenecks; guidance for 2021 adjusted

GRENKE AG / Key word(s): Forecast
GRENKE AG: GRENKE AG: New leasing business in the third quarter adversely affected by supply bottlenecks; guidance for 2021 adjusted

04-Oct-2021 / 20:18 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


GRENKE AG: New leasing business in the third quarter adversely affected by supply bottlenecks; guidance for 2021 adjusted

Baden-Baden, October 4, 2021: GRENKE AG, a global financing partner for small and medium-sized enterprises, achieved new leasing business of EUR 372.2 million in the third quarter of 2021 (Q3 2020: EUR 517.6 million). Global supply bottlenecks, specifically at manufacturers of computer and office equipment, were the cause of the weaker year-on-year new leasing business. The contribution margin 2 declined slightly in the third quarter due to refinancing costs and amounted to 17.1% (Q3 2020: 18.4%). New business volume is the total acquisition cost of all newly purchased leased assets.

As a result of the current developments, the Company has adjusted its guidance for new leasing business in the current financial year to EUR 1.5 billion to EUR 1.7 billion (previously EUR 1.7 billion to EUR 2.0 billion). The forecast for net profit in the current financial year remains unchanged at EUR 60 million to EUR 80 million.

For further information, please contact:

GRENKE AG
Anke Linnartz
Director Investor Relations
Neuer Markt 2
76532 Baden-Baden
Phone: +49 7221 5007-204
Email: investor@grenke.de
Website: www.grenke.de

Press contact
Stefan Wichmann
Executive Communications Consulting
Neuer Markt 2
76532 Baden-Baden
Email: presse@grenke.de
Mobile: +49 (0) 171 20 20 300


04-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021